Revvity reported second quarter 2026 results that exceeded analyst expectations, driven by strong performance in its Diagnostics segment. The company posted total revenue of $730 million and an adjusted EPS from continuing operations of $1.41. Concurrently, Revvity announced a definitive agreement to divest its Immunodiagnostics business in China and raised its full-year 2026 guidance.
Key Highlights
- Second quarter revenue of $730 million and adjusted EPS of $1.41 beat consensus estimates of $703.2 million and $1.23, respectively. The adjusted EPS figure includes an approximate $0.11 benefit from tariff-related refunds.
- On a pro forma basis, organic revenue grew 3% year-over-year, surpassing the 2.0% analyst estimate, driven by strong growth in the Diagnostics segment.
- The Diagnostics segment reported a 12% increase in pro forma revenue and 11% pro forma organic growth, which offset a 2% decline in pro forma revenue and a 3% pro forma organic decline in the Life Sciences segment.
- Revvity raised its full-year 2026 pro forma guidance, now forecasting total revenue of $2.83-$2.86 billion and adjusted EPS of $5.30-$5.40.